TAK-259
TAK-259 is an orally active α1D-adrenergic receptor antagonist with a Ki value of 1.1 nM for human α1D-adrenergic receptors. TAK-259 can inhibit the contraction of isolated bladder strips in rats with bladder outlet obstruction, reduce non-voiding bladder contractions, and improve urinary frequency symptoms. TAK-259 can be used in research related to overactive bladder.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 1192348-73-4
- 分子式: C14H13Cl2N3O3S
- 分子量:374.24
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
Adrenergic Receptor アイソフォーム固有の製品をすべて表示
More
生物活性
|
Alpha-1D adrenergic receptor 1.1 nM (Ki) |
TAK-259 (Compound 9u) (60 min) potently binds to human α1D-adrenergic receptor in a cell membrane-free binding assay, with a Ki value of 1.1 nM[1].
TAK-259 (10 μM; 5 min at 32°C) exhibits low inhibitory activity against hERG K+ channels in cell-based patch-clamp assays (16% inhibition at 10 μM)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
TAK-259 (10 µg/kg; p.o.) reduces micturition frequency in Cyclophosphamide (HY-17420)-induced cystitis rats when administered at the minimum effective dose of 10 µg/kg[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
化学情報
-
CAS 番号 1192348-73-4
-
分子量 374.24
-
分子式 C14H13Cl2N3O3S
-
SMILES
O=C(C1=CC(Cl)=CN(CC2=CC(Cl)=CC=C2S(=O)(C)=O)C1=N)N
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[2]. Sakauchi N, et al. Discovery of 5-Chloro-1-(5-chloro-2-(methylsulfonyl)benzyl)-2-imino-1,2-dihydropyridine-3-carboxamide (TAK-259) as a Novel, Selective, and Orally Active α1D Adrenoceptor Antagonist with Antiurinary Frequency Effects: Reducing Human Ether-a-go-go-Related Gene (hERG) Liabilities. J Med Chem. 2016 Apr 14;59(7):2989-3002. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
TAK-259 関連分類
HY-120473 関連分類
Powered by Bioz